Bli medlem
Bli medlem

Du är här

2021-07-26

Episurf: Clinical results (5 yrs) for Episealer® accepted for presentation at the ISAKOS 2021 Global Congress

Episurf Medical (Nasdaq: EPIS B) today announces that an abstract with results from a Swedish multicentre clinical study with 5 years' follow-up of Episealer® Knee patients has been accepted for presentation at the upcoming ISAKOS 2021 Global Congress. The abstract, "Good Subjective Outcome And Low Risk Of Revision Surgery With A Novel Customized Metal Implant For Focal Femoral Chondral Lesions At A Minimum Of Five Years Follow-Up", will be presented by Associate Professor Anders Stålman, Capio Artro Clinic, Stockholm, Sweden.

ISAKOS (International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine) is an international organisation with the mission to advance the worldwide exchange and dissemination of education, research and patient care in arthroscopy, knee surgery and orthopaedic sports medicine. The ISAKOS 2021 Global Congress will be held online on November 27-28.

The abstract reports on the clinical outcome of the 10 first Swedish Episealer® patients, that have undergone treatment with Episurf Medical's individualised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee.

"We have now come to a stage where we see mid- to long-term results being available for presentation and publication and we are pleased that this scientific abstract with clinical results from the very first Swedish Episealer® patients has been accepted for presentation at this international congress", says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.